Loading insider details...
Beta
Latest Form 4 (Oct 13, 2026): Grant/Award of 2,465 ANTX shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 13, 2026 | AN2 Therapeutics, Inc. (ANTX) | Grant/Award | 2,465 | n/a |
| Jul 10, 2026 | AN2 Therapeutics, Inc. (ANTX) | Grant/Award | 2,852 | n/a |
| Apr 11, 2026 | AN2 Therapeutics, Inc. (ANTX) | Grant/Award | 3,775 | n/a |
| Mar 23, 2026 | AN2 Therapeutics, Inc. (ANTX) | Grant/Award | 20,724 | n/a |
| Feb 23, 2026 | AN2 Therapeutics, Inc. (ANTX) | Grant/Award | 20,400 | n/a |
| Jan 14, 2026 | AN2 Therapeutics, Inc. (ANTX) | Grant/Award | 11,560 | n/a |
| Oct 14, 2025 | AN2 Therapeutics, Inc. (ANTX) | Grant/Award | 10,367 | n/a |
| Jul 11, 2025 | AN2 Therapeutics, Inc. (ANTX) | Grant/Award | 11,875 | n/a |
| May 23, 2025 | AN2 Therapeutics, Inc. (ANTX) | Grant/Award | 19,111 | n/a |
| Apr 11, 2025 | AN2 Therapeutics, Inc. (ANTX) | Grant/Award | 9,705 | n/a |